Format

Send to

Choose Destination
Ann Intern Med. 1989 Aug 15;111(4):273-9.

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

Author information

1
Johns Hopkins Oncology Center, Baltimore, Maryland.

Abstract

STUDY OBJECTIVE:

To assess the activity of taxol in patients with advanced, progressive, and drug-refractory ovarian cancer and to delineate more clearly the toxicity of taxol in this patient population.

DESIGN:

Nonrandomized, prospective phase II trial.

PATIENTS:

Forty-seven patients with drug-refractory epithelial ovarian cancer who had one or more lesions measurable in perpendicular diameters. Of these patients, 45 were evaluable for toxicity and 40 were evaluable for response.

INTERVENTIONS:

PATIENTS were treated every 22 days with varying doses of taxol (110 to 250 mg/m2 body surface) given as a 24-hour infusion with subsequent doses based on adverse effects. A premedication regimen was used to avoid acute hypersensitivity reactions.

MEASUREMENTS AND MAIN RESULTS:

Twelve patients (30%; CI, 16% to 44%) responded to taxol for periods lasting from 3 to 15 months. The dose-limiting toxicity was myelosuppression with leukocytes affected more severely and commonly than thrombocytes or reticulocytes. Leukopenia was usually brief in duration but was associated with sepsis in 3 cases (2 fatal). Other adverse effects included myalgias, arthralgias, alopecia, diarrhea, nausea, vomiting, mucositis, and peripheral neuropathy. Rare cases of cardiac and central neurotoxicity were also noted.

CONCLUSIONS:

Taxol is an active agent in drug-refractory ovarian cancer and deserves further study in combination with other active drugs in previously untreated patients with advanced ovarian cancer.

PMID:
2569287
DOI:
10.7326/0003-4819-111-4-273
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center